Roche U-turns and Adaptimmune wins
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
Fate delivers, up to a point
The first human data from the Car-NK project FT596 are impressive – but not impressive enough for a company worth $9bn.
Fate looks to justify its $9bn valuation
The glacial development of Fate’s anti-CD19 Car-NK therapy FT596 could yield real data at last.
Asco 2021 movers – PDS wins, but big pharma reigns
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Can we freeze them? Yes we can, says Nkarta
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
Nantkwest tries to catch the NK cell wave
Nantkwest claims efficacy with its most advanced NK cell therapy but, as ever with Patrick Soon-Shiong companies, it’s complicated.
Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Ash 2020 cell therapy preview – the battle for recognition
With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
